Recursion Publishes Second Annual Environmental, Social and Governance Report
28 Marzo 2023 - 2:14PM
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading
the space by decoding biology to industrialize drug discovery,
today announced the release of its second annual Environmental,
Social and Governance (ESG) Report. The report highlights the
company’s approach, practices and goals in several important areas
such as its commitment to patients, social and community impact,
people and culture, environmental sustainability, and governance.
“As a company focused on using cutting-edge technology to find
solutions to some of the most complex and pressing problems in
biotechnology, we have the opportunity to create massive positive
impact in the world and build an incredible business to drive it,”
said Chris Gibson, Ph.D., Co-Founder and Chief Executive Officer at
Recursion. “In our second annual ESG report, we outline how our
work in 2022 to industrialize drug discovery is in direct support
of our vision to create a more sustainable future - not only to
benefit patients, but also our employees, partners, communities,
and the broader healthcare and technology innovation
ecosystems.”
Since publishing its inaugural ESG report last year, Recursion
has received several recognitions for its commitment to excellence
in ESG. Institutional Shareholder Services (ISS) awarded Recursion
a Prime Rating for ESG performance in 2022, which recognizes
companies with ESG performance above a sector-specific threshold
and is defined by ISS as "absolute best in class." Additionally, as
of October 2022, Recursion was ranked 98 out of over 850 companies
(approximately top 10%) in the pharmaceutical category by
Morningstar Sustainalytics, which gives an in-depth analysis of a
company’s ESG performance and compares it to industry peers. In
February 2023, Recursion received an MSCI ESG Rating of A.
Recursion’s ESG Report is guided by key ESG frameworks, notably
the standards of the Sustainability Accounting Standards Board
(SASB) and the United Nations Sustainable Development Goals (UN
SDGs). You can learn more about Recursion’s approach to ESG and
download a copy of the report at www.Recursion.com/esg.
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological and chemical datasets. Recursion leverages
sophisticated machine-learning algorithms to distill from its
dataset a collection of trillions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating one of the most powerful supercomputers in the world,
Recursion is uniting technology, biology and chemistry to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding early and late stage discovery,
preclinical, and clinical programs; licenses and collaborations;
prospective products and their potential future indications and
market opportunities; Recursion OS and other technologies; business
and financial plans and performance; and all other statements that
are not historical facts. Forward-looking statements may or may not
include identifying words such as “plan,” “will,” “expect,”
“anticipate,” “intend,” “believe,” “potential,” “continue,” and
similar terms. These statements are subject to known or unknown
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements,
including but not limited to: challenges inherent in pharmaceutical
research and development, including the timing and results of
preclinical and clinical programs, where the risk of failure is
high and failure can occur at any stage prior to or after
regulatory approval due to lack of sufficient efficacy, safety
considerations, or other factors; our ability to leverage and
enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading “Risk Factors” in our
filings with the U.S. Securities and Exchange Commission, including
our Annual Report on Form 10-K. All forward-looking statements are
based on management’s current estimates, projections, and
assumptions, and Recursion undertakes no obligation to correct or
update any such statements, whether as a result of new information,
future developments, or otherwise, except to the extent required by
applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024